These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
470 related articles for article (PubMed ID: 15958636)
1. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Wu CJ; Biernacki M; Kutok JL; Rogers S; Chen L; Yang XF; Soiffer RJ; Ritz J Clin Cancer Res; 2005 Jun; 11(12):4504-11. PubMed ID: 15958636 [TBL] [Abstract][Full Text] [Related]
2. CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Yang XF; Wu CJ; Chen L; Alyea EP; Canning C; Kantoff P; Soiffer RJ; Dranoff G; Ritz J Cancer Res; 2002 Oct; 62(19):5517-5522. PubMed ID: 12359762 [TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168 [TBL] [Abstract][Full Text] [Related]
4. Stage- and lineage-specific expression of the HOXA10 homeobox gene in normal and leukemic hematopoietic cells. Lawrence HJ; Sauvageau G; Ahmadi N; Lopez AR; LeBeau MM; Link M; Humphries K; Largman C Exp Hematol; 1995 Oct; 23(11):1160-6. PubMed ID: 7556525 [TBL] [Abstract][Full Text] [Related]
6. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Yang XF; Wu CJ; McLaughlin S; Chillemi A; Wang KS; Canning C; Alyea EP; Kantoff P; Soiffer RJ; Dranoff G; Ritz J Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7492-7. PubMed ID: 11416219 [TBL] [Abstract][Full Text] [Related]
7. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Biernacki MA; Marina O; Zhang W; Liu F; Bruns I; Cai A; Neuberg D; Canning CM; Alyea EP; Soiffer RJ; Brusic V; Ritz J; Wu CJ Cancer Res; 2010 Feb; 70(3):906-15. PubMed ID: 20103624 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease. Krauth MT; Simonitsch I; Aichberger KJ; Mayerhofer M; Sperr WR; Sillaber C; Schneeweiss B; Mann G; Gadner H; Valent P Am J Clin Pathol; 2004 Apr; 121(4):473-81. PubMed ID: 15080298 [TBL] [Abstract][Full Text] [Related]
9. The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia. Aumann K; Lassmann S; Schöpflin A; May AM; Wöhrle FU; Zeiser R; Waller CF; Hauschke D; Werner M; Brummer T Hum Pathol; 2011 May; 42(5):719-26. PubMed ID: 21292300 [TBL] [Abstract][Full Text] [Related]
10. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644 [TBL] [Abstract][Full Text] [Related]
11. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia. Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497 [TBL] [Abstract][Full Text] [Related]
12. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882 [TBL] [Abstract][Full Text] [Related]
13. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia]. Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968 [TBL] [Abstract][Full Text] [Related]
14. Expression of nucleolar antigen p145 in bone marrow cells of patients with myeloid leukemias. Raza A; Imren S; Gezer S; Verkh L; Freeman JW Cancer Res; 1989 Jan; 49(2):482-7. PubMed ID: 2910466 [TBL] [Abstract][Full Text] [Related]
15. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging]. Wu Y; Chen YZ; Huang HF; Chen P; Lu LH Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661 [TBL] [Abstract][Full Text] [Related]
16. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction]. Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019 [TBL] [Abstract][Full Text] [Related]
17. Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia. Lanza F; Bi S; Castoldi G; Goldman JM Leukemia; 1993 Oct; 7(10):1570-5. PubMed ID: 7692192 [TBL] [Abstract][Full Text] [Related]
19. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model. Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059 [TBL] [Abstract][Full Text] [Related]
20. Severe functional alterations in vitro in CD34(+) cell subpopulations from patients with chronic myeloid leukemia. Chávez-González A; Rosas-Cabral A; Vela-Ojeda J; González JC; Mayani H Leuk Res; 2004 Jun; 28(6):639-47. PubMed ID: 15120942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]